Abstracts tagged "B cells"

Abstract Number: 1822 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus
Mukul Minocha¹, Shekman Wong², Jiewei Zeng², Peng Lu³, Jeroen Medema² and Ahmed Othman⁴, ¹Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Worcester, MA, ⁴AbbVie, North Chicago, IL
Background/Purpose: Selective Inhibition of Bcl-2 pathway may offer clinical efficacy in Systemic Lupus Erythromatosus (SLE) by restoring apoptosis in autoreactive cells, which may lead to…
Abstract Number: 502 • 2015 ACR/ARHP Annual Meeting
Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Jennifer Barnard¹, Nida Meednu², Kelly Callahan¹, Karen Boyle³, Lynette Keyes-Elstein³, Beverly Welch⁴, Ellen Goldmuntz⁵ and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵DAIT, NIAID/NIH, Bethesda, MD
Background/Purpose: TNF is a key pro-inflammatory cytokine in normal immune responses and pathologically in the rheumatoid arthritis (RA) synovium, thus representing a key treatment target…
Abstract Number: 1110 • 2015 ACR/ARHP Annual Meeting
A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
Charlotte Hua¹, Rachel Audo², Nataliya Yeremenko³, Dominique Baeten⁴, Michael Hahne², Bernard Combe⁵, Jacques Morel⁵ and Claire I. Daien⁵, ¹Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²IGMM-CNRS UMR5535, Montpellier, France, ³Academic medical center, University of Amsterdam, Amsterdam, France, ⁴1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B-cell functions are impaired in…
Abstract Number: 1848 • 2015 ACR/ARHP Annual Meeting
Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and Its Clinic Significance
Wei Kong, Wei Deng, Xuebing Feng, Genhong Yao, Weiwei Chen, Xiaojun Tang, Yue Sun, Saisai Huang, Zhuoya Zhang, Bingyu Shi and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease manifested by multiorgan impairment including glomerulonephritis, cutaneous lesions and arthritis. B cells participate in the onset…
Abstract Number: 602 • 2015 ACR/ARHP Annual Meeting
Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study
Padmanabha Shenoy¹ and Manish Bavaliya², ¹Dept. of rheumatology and clinical immunology, Amrita Institute of medical science and research institute, Kochi, India, ²Department of rheumatology and clinical immunology, Amrita institute of medical sciences and research institute, Kochi, India
Background/Purpose: Rituximab is an anti-CD20 antibody that represents a therapeutic alternative for the patients with rheumatoid arthritis. It has been proven that rituximab at a…
Abstract Number: 1113 • 2015 ACR/ARHP Annual Meeting
B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab
Michelle T. Ngo¹, Abigail Benitez², Kimberly J. Payne², Michael De Vera³, Terry Ann Milford² and Karina Marianne D. Torralba⁴, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA
Background/Purpose: The B cell pool is composed of subsets with different phenotypes and functions that mainly have effector functions to maintain immunologic tolerance. These…
Abstract Number: 1853 • 2015 ACR/ARHP Annual Meeting
Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE
Asiya Chida¹, Kevin Cashman¹, Scott Jenks², Louise Hartson¹, Youliang Wang¹, Quan-Zhen Li Li^3,4, Chandra Mohan⁵ and Ignacio Sanz^6,7, ¹Medicine, Emory University, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Immunology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Biomedical Engineering, University of Houston, Houston, TX, ⁶Rheumatology, Emory University, Atlanta, GA, ⁷Medicine/Rheumatology, Emory University, Atlanta, GA
Background/Purpose: IgG antibodies expressing the idiotope for the 9G4 idiotype, the framework-1 hydrophobic patch (HP) of VH4-34, are expanded in SLE and provide a unique…
Abstract Number: 729 • 2015 ACR/ARHP Annual Meeting
The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Cosmin Dascalu¹, Anne Davidson², Meggan C. Mackay³, Richard Furie⁴, Weiqing Huang⁵ and Cynthia Aranow⁶, ¹Medicine/Rheumatology, North Shore- Long Island Jewish, Manhasset, NY, ²Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ³Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…
Abstract Number: 1114 • 2015 ACR/ARHP Annual Meeting
Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity
Sarah Kongpachith¹, WH Robinson¹, Sara Rasmussen², Robert Clancy³ and Jill P. Buyon³, ¹Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL) is an uncommon autoimmune disease classically manifest as permanent complete heart block and/or transient cutaneous lesions. By definition of NL, there…
Abstract Number: 1922 • 2015 ACR/ARHP Annual Meeting
Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis
Nicolas Dumoitier^1,2,3,4, Sebastien Lofek^2,3,5, Alexis Regent⁶, Jonathan London⁷, Benjamin Chaigne^1,2,3,8, Benjamin Terrier^2,7,9,10, Nadine Varin-Blank^4,11 and Luc Mouthon^1,2,4,6, ¹Infection, Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, ²CNRS, UMR8104, Paris, France, ³Université Paris Descartes, Paris, France, ⁴Labex Inflamex, Université Sorbonne Paris Cité, Paris, France, ⁵Infection,Immunité, Inflammation, Institut Cochin, INSERM U1016, Paris, France, ⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁷Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁸Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochinl, Paris, France, ⁹Infection, Immunité, Inflammation, Institut Cochin INSERM U1016, Paris, France, ¹⁰Université Paris Descartes, paris, France, ¹¹UFR SMBH, INSERM, UMR978, Bobigny, France
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease characterized by fibroblasts activation, increased extra-cellular matrix synthesis associated with autoimmunity. However, the potential role…
Abstract Number: 738 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Peng Lu¹, Roy Fleischmann², Craig Curtis³, Stanislav Ignatenko⁴, Monali Desai⁵, Shekman L. Wong⁵, Kristie M. Grebe¹, Jiewei Zeng⁵, Jeroen Medema⁵ and James Stolzenbach⁵, ¹AbbVie Inc., Worcester, MA, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Compass Research Center, Orlando, FL, ⁴Charité Research Organization, Berlin, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Apoptosis is needed to eliminate auto-reactive T and B cells during immune responses; failure of elimination is important in development of systemic lupus erythematosus…
Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…
Abstract Number: 1934 • 2015 ACR/ARHP Annual Meeting
Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus
Maud Wilhelm¹, Fengjuan Wang², Nicolas Schall², Michael Faludi³, Jean Francois Kleinmann⁴, Emil P. Nashi⁵, Thierry Martin⁶, Jean Sibilia⁷, Jean-Louis Pasquali⁸, Daniel Wallace⁹ and Sylviane Muller¹⁰, ¹Immunopathologie & Chimie Thérapeutique, CNRS, Strasbourg, France, ²CNRS, Strasbourg, France, ³761 Graham, McGill University, Mont-Royal, QC, Canada, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Cnrs UPR9021, IBMC, Strasbourg, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁸Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ⁹Cedars-Sinai/UCLA, Los Angeles, CA, ¹⁰CNRS Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
Background/Purpose: P140 is a 21-mer peptide (sequence 131-151, phosphorylated at position 140) that is derived from the spliceosomal protein U1-70K. In a multicenter, randomized, placebo-controlled…
Abstract Number: 1052 • 2015 ACR/ARHP Annual Meeting
Identification of Novel Sjogren’s Syndrome Risk Loci in the Regions of TNFAIP3 and PRDM1
Christopher J. Lessard^1,2, He Li^1,2, John Ice², Indra Adrianto³, Astrid Rasmussen², Kiely Grundahl⁴, Jennifer A. Kelly⁵, Corinne Miceli⁶, Simon Bowman⁷, Susan Lester⁸, Johan G. Brun^9,10, Lasse G. Goransson¹¹, Erna Harboe¹¹, Joel M. Guthridge², Kenneth M. Kaufman^12,13, Per Eriksson¹⁴, Maija-Leena Eloranta¹⁵, Marika Kvarnström¹⁶, Deborah S. Cunninghame-Graham¹⁷, A. Darise Farris², Michael T. Brennan¹⁸, James Chodosh¹⁹, Raj Gopalakrishnan²⁰, Andrew J.W. Huang²¹, Pamela Hughes²², David M. Lewis²³, Lida Radfar²⁴, Michael D. Rohrer²⁵, Donald U. Stone²⁶, Timothy J. Vyse¹⁷, Patrick M. Gaffney², Judith A. James^1,5,27, John B. Harley^12,28, Roald Omdal¹¹, Marie Wahren-Herlenius¹⁶, Gabor G. Illei²⁹, Torsten Witte³⁰, Roland Jonsson^10,31, Maureen Rischmueller^32,33, Lars Rönnblom³⁴, Xavier Mariette³⁵, Juan-Manuel Anaya³⁶, Wan-Fai Ng³⁷, Gunnel Nordmark³⁴, Courtney G. Montgomery², Nelson L. Rhodus³⁸, Barbara M. Segal³⁹, R. Hal Scofield^2,27,40 and Kathy L. Sivils^1,2, ¹Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁵Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, PARIS, France, ⁷Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ⁸Queen Elizabeth Hospital, Adelaide, Australia, ⁹Institute of Internal Medicine, University of Bergen, Bergen, Norway, ¹⁰Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ¹¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹²US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden, ¹⁵Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁶Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ¹⁸Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹⁹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ²⁰Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ²¹Department of Ophthalmology and Visual Sciences, Washington University, St Louis, MO, ²²Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ²³College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ²⁵Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁶Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁷Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁸Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁹National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, ³⁰Hannover Medical School, Hanover, Germany, ³¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ³²University of Adelaide, Adelaide, Australia, ³³Department of Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³⁴Rheumatology, Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ³⁵AP-HP, Hopitaux Universitaires Paris-Sud, Université Paris-Sud, Paris, France, ³⁶Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ³⁷Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁸Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁹Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ⁴⁰US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a complex autoimmune disease with both environmental and genetic factors playing important roles in its pathophysiology. The goal of this…
Abstract Number: 1116 • 2015 ACR/ARHP Annual Meeting
Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients
Scott Jenks¹, Benjamin Barwick² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Emory University, Altanta, GA, ³Medicine, Emory University, Atlanta, GA
Background/Purpose: B cell homeostasis is perturbed in SLE patients; in particular many patients with active disease have a large expansion of IgD- CD27- B cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].